Loading clinical trials...

Artificial Pancreas in Latin America | Clinical Trials | Clareo Health

COMPLETEDNA

Artificial Pancreas in Latin America

Pilot Study of Automatic Glycaemic Correction Systems (Closed-loop) in Patients With Type 1 Diabetes Mellitus With Continuous Subcutaneous Insulin Infusion

NCT02994277•Hospital Italiano de Buenos Aires

View on ClinicalTrials.gov

Summary

The purpose of this study is to use closed-loop systems with the algorithms designed by the University of Virginia and by the Instituto Tecnologico de Buenos Aires (ITBA)/ Universidad Nacional de La Plata (UNLP)/ Universidad Nacional de Quilmes (UNQ) to determine the infusion of insulin in a prolonged period of time in patients with type 1 diabetes mellitus (T1DM).

Detailed Description

Aims: 1. To test University of Virginia closed-loop algorithm with meal announcement for 36 hours at our facilities. 2. To test the ability of the closed-loopInstituto Tecnologico de Buenos Aires (ITBA)/ Universidad Nacional de La Plata (UNLP)/ Universidad Nacional de Quilmes (UNQ) algorithm without meal announcement to maintain glucose control for 2 periods of 12 hours In both cases, the adequate operation of the system will be considered verified if the system works properly at least 80% of the total connection time .

Eligibility

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patient have been diagnosed with T1DM at least two years ago and have been using an insulin pump and a CGM for at least 6 months prior to the trial first visit.
•Patient is \>18 and \<65 years.
•Patient has HbA1c \> 6.5 % and \< 10%.
•Woman in premenopausal age agrees to use contraceptive methods.
•Woman in premenopausal age has negative B-HCG in the tests performed in the trial.
•Patient is trained in carbohydrates counting.
•Patient has signed informed consent and has the ability to understand the nature and intent of the study including the ability to comply with study procedures and is willing to keep scheduled visits.

Exclusion Criteria

•Patient has been hospitalized for diabetic ketoacidosis in the last 12 months.
•Patient has experienced severe hypoglycemia with loss of consciousness in the last 12 months.
•Patient has a history of coronary disease or cardiac failure.
•Patient with uncontrolled arterial hypertension.
•Patient with a condition that makes the researcher believe that it might increase the chance of hypoglycemia.
•Patient has symptoms compatible with an active infectious disease.
•Patient has Cystic Fibrosis.
•Pregnant women, or women with the intention of getting pregnant; women breastfeeding.
•Patient has been hospitalized for psychiatric treatment in the last 6 months.
•Patient with a diagnosis of an adrenal disease.
+5 more criteria

Key Dates

Start Date

November 1, 2016

Primary Completion Date

July 6, 2017

Completion Date

July 7, 2017

Last Updated

September 12, 2025

Enrollment

ACTUAL participants

Conditions

Diabetes

Interventions

1° Phase: UVa algorithm 2° Phase: ITBA/UNLP algorithm

DEVICE

Feasibility of a Tailored Online Self-compassion Intervention

NCT07051005

Type 1 Diabetes MellitusType 2 Diabetes Mellitus (T2DM)

View study

RECRUITING

Genetic Studies of Insulin and Diabetes

NCT00001987

Diabetes MellitusSevere Insulin Resistance

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 12, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Artificial Pancreas in Latin America

Inclusion Criteria

Exclusion Criteria

Feasibility of a Tailored Online Self-compassion Intervention

Genetic Studies of Insulin and Diabetes

Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)

Mesenchymal Stem Cell and Exosome Therapy for Diabetic Erectile Dysfunction

A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes

iGlarLixi CGM Study in Chinese T2D Individuals After OADs